Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Regeneron Pharmaceutical (REGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 36,501,464
  • Shares Outstanding, K 109,276
  • Annual Sales, $ 6,711 M
  • Annual Income, $ 2,444 M
  • 60-Month Beta 1.18
  • Price/Sales 5.43
  • Price/Cash Flow 15.01
  • Price/Book 4.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 5.24
  • Number of Estimates 1
  • High Estimate 5.24
  • Low Estimate 5.24
  • Prior Year 3.98
  • Growth Rate Est. (year over year) +31.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
329.00 +4.60%
on 04/22/19
415.89 -17.25%
on 04/02/19
-47.66 (-12.16%)
since 03/22/19
3-Month
329.00 +4.60%
on 04/22/19
442.00 -22.14%
on 03/04/19
-57.07 (-14.22%)
since 01/23/19
52-Week
281.89 +22.08%
on 05/09/18
442.00 -22.14%
on 03/04/19
+28.13 (+8.90%)
since 04/23/18

Most Recent Stories

More News
Global Ophthalmology Therapeutics Market 2019-2023 - Key Players are Allergan, F. Hoffmann-La Roche, Novartis, Regeneron Pharmaceuticals, and Santen Pharmaceutical - ResearchAndMarkets.com

The "Global Ophthalmology Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

REGN : 344.14 (+3.03%)
Shares of REGN Down 17.2% Since Downtrend Call on Shares

SmarTrend identified a Downtrend for Regeneron Pharm (NASDAQ:REGN) on March 8th, 2019 at $403.55. In approximately 2 month, Regeneron Pharm has returned 17.23% as of today's recent price of $334.03.

REGN : 344.14 (+3.03%)
SmarTrend Watching for Potential Rebound in Shares of Regeneron Pharm After 4.68% Loss

Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $350.50 to a high of $363.09. Yesterday, the shares fell 4.7%, which took the trading range below the 3-day low of...

REGN : 344.14 (+3.03%)
Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran

Alnylam (ALNY) initiates phase III study on lumasiran and also reports new positive efficacy results from the ongoing phase II open-label extension (OLE) study on the same.

MDCO : 29.37 (+3.45%)
ALNY : 87.41 (+5.11%)
NVS : 75.90 (+0.66%)
REGN : 344.14 (+3.03%)
Novartis' (NVS) BLA for Ophthalmology Drug Accepted by FDA

The FDA accepts Novartis' (NVS) BLA seeking approval for brolucizumab for the treatment of wet AMD.

NVS : 75.90 (+0.66%)
RHHBY : 32.8900 (+1.26%)
REGN : 344.14 (+3.03%)
GSK : 40.22 (+1.36%)
Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran

Alnylam (ALNY) reports complete positive results from the phase III ENVISION study of givosiran for the treatment of acute hepatic porphyria.

MDCO : 29.37 (+3.45%)
ALNY : 87.41 (+5.11%)
NVS : 75.90 (+0.66%)
REGN : 344.14 (+3.03%)
Regeneron Pharm Falls 1.94% on Heavy Volume: Watch For Potential Rebound

Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $385.86 to a high of $389.43. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of...

REGN : 344.14 (+3.03%)
4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics

We take a look at companies, which have been developing treatments for various diseases using RNAi technology.

ABUS : 2.99 (-5.08%)
DRNA : 13.99 (+1.08%)
ARWR : 19.07 (+2.91%)
ALNY : 87.41 (+5.11%)
REGN : 344.14 (+3.03%)
MRNA : 24.70 (+4.53%)
Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More

Key highlights of the past week are new drug approvals, collaborations and pipeline updates.

CELG : 93.67 (+0.27%)
ALNY : 87.41 (+5.11%)
GILD : 63.04 (+1.89%)
REGN : 344.14 (+3.03%)
AMGN : 179.76 (+1.93%)
UTHR : 104.31 (+5.53%)
Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics

Regeneron (REGN) extends collaboration agreement with Alnylam to develop new RNAi therapeutics for diseases of the eye and central nervous system (CNS).

BAYRY : 17.3650 (+1.25%)
ALNY : 87.41 (+5.11%)
REGN : 344.14 (+3.03%)
SNY : 41.71 (+0.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade REGN with:

Business Summary

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma...

See More

Key Turning Points

2nd Resistance Point 353.93
1st Resistance Point 349.03
Last Price 344.14
1st Support Level 336.85
2nd Support Level 329.57

See More

52-Week High 442.00
Fibonacci 61.8% 380.84
Fibonacci 50% 361.95
Last Price 344.14
Fibonacci 38.2% 343.05
52-Week Low 281.89

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar